Nanoscope Therapeutics Inc.’s Post

Uncover the Secrets of Biotech IT Evolution: Dive into the 'Calculus of IT' with Nathan McBride of Xilio Therapeutics, Inc. As the biotech industry surges forward, it is imperative to grasp the fundamental elements that define success. From do's and don'ts that can make or break a biotech's journey to finely-tuned launchpad strategies tailored for emerging players in the field, Nate delves into it all in our on-demand video. Watch the whole video here: bit.ly/44oJkq8 For more videos from our Life Sciences Summit, visit: bit.ly/3QwcFeU #LifeSciences #Biotech #ClinicalTrials

Are you attending RESI Boston next week? If so, join Portal and Radyus Research for a panel discussion with our Director of Lab and Scientific Operations, Krisha Panchalingam! This panel will discuss maximizing pre-clinical development success for VC-backed startups through CRO partnerships. Additional information is below, and we hope to see you there!

The life sciences sector continues to grow in the golden triangle as reported here by Evelina Grecenko If you wish to follow other such stories or understand the data behind the growth please feel free to get in touch. #lifescience #EG #CRE #data #property #Intelligence

Take two minutes to watch our teaser trailer to learn more about how BigHat Biosciences uses AI/ML and synthetic biology to develop better antibodies faster.

📣 Meet DIVERSA at #BIOSPAIN2023, held on the 26-28th of September in Barcelona.  ✅ Biospain is the main biotechnology event held in Spain and one of the most important in Europe. It brings together more than 850 innovative entities, and DIVERSA will be one of these! We have registered in the partnering program! This process begins well in advance of the event. You can find DIVERSA, Thanks to the One-on-One Partnering™ software, and schedule a meeting with us!  AseBio - Asociación Española de Empresas Biotecnológicas organizes the event in collaboration with Generalitat de Catalunya, Biocat, BioRegion of Catalonia, and Barcelona City Council. 👉🏻 Read more about our participation in our blog (link in the first comment) #drugdelivery #nanooncology #nanomedicine #biotechnology

A 12-year-old Swiss biotech seeks to make its mark in the space of anti-tau Alzheimer's medicines, and it's moving ahead in the same niche as the field's two biggest drugmakers: Eli Lilly and Biogen. With a $100 million Series C, Asceneuron hopes to prove that an O-GlcNAcase (OGA) inhibitor can help thwart or slow down cognitive declines and do so with an oral treatment, rather than complex and healthcare-straining infusions. “Lilly will hopefully validate this class later on this year, and then we are second after that in a very large market,” Naveed Siddiqi said in an interview with Endpoints News. The Novo Holdings venture investments senior partner said it’s believed that tau is “more highly correlated with the loss of your cognition than amyloid is.” More from my interview with Asceneuron SA's CEO Barbara A. and Ryan S.: #alzheimers #tau #dementia #alzheimersresearch #drugdevelopment #ogainhibitor #biotech #venturecapital

A must read published by Austria Wirtschaftsservice: #aws brochure on projects and companies supported through the #Preseed and #Seedfinancing programs in 2022. As these programs require an in-depth due diligence process, this publication is a great resource for the #VC and #PE community looking for quality investment opportunities! The list includes aitiologic | HD Immune | Holloid | VERDI Solutions | Ascense Medical GmbH | Brightmind.AI | Cellectric Biosciences | Hypericum LifeScience | RIANA Therapeutics | Tridem Bioscience | Innotonix | Fermify from #Vienna and ABS Biotechnologies GmbH | Enzyan Biocatalysis GmbH | NEUROLENTECH GmbH | sendance GmbH | c-square bioscience | Lignovations from other regions across #Austria. Booklets from previous years including many more candidates for investment or licensing deals are available for download on our website: https://lnkd.in/dBb9mSWc #deeptech #lifesciences

🇪🇪 Estonian-origin international founders in biotech continue to inspire and serve as role models for our small community. Recently, several of these Estonian-linked global trailblazers have closed and announced significant seed rounds, showcasing the strength and potential of our smart biotech founders. ExpressionEdits from 🇬🇧 UK has closed a $13 million USD round led by Octopus Ventures and redalpine. Major co-investors include BlueYard Capital, Wilbe.com, Acequia Capital, Amino Collective, and Hawktail. ExpressionEdits maintains strong ties to the Estonian biotech community. Both, the CEO, Dr. Kärt Tomberg, and the CTO, Dr. Leopold Parts, are Estonian-born talented scientists. The Wilbe.com mentoring program has generously contributed to the development of Estonian founders mindset through their BSF Courses (Estonians - check this out!). Radar Therapeutics from 🇺🇸 US has raised $13.4 million USD in Seed Funding to develop programmable genetic and mRNA-based therapeutics that use RNA sensors. This round, led by NFX Bio, included major players such as Eli Lilly and Company, Biovision Ventures, and KdT Ventures. The CSO of Radar Therapeutics is Estonian-born talented computational scientist Eerik Kaseniit. Additionally, CoSyne Therapeutics from 🇬🇧 has closed about $8.8 million USD to develop polymathic AI for drug discovery and development. Their CSO, Dr. Liisi Laaniste, is also an Estonian-born scientist. What a panel, huh!? The Estonian biotech community continues to grow and push the boundaries of innovation globally. This promising beginning marks the start of a transformative journey—not just for patients, but also for founders.

🚀ELRIG DRUG DISCOVERY 2023 is around the corner, and we're thrilled to be a part of it. Our Chief R&D Officer, Adam Davenport, PhD, and Head of Drug Discovery Programs & Partnerships, Tom Coulter, PhD, are geared up to explore the latest breakthroughs in drug discovery. 💊 Let's discuss collaboration, innovation, and the future of drug discovery research. See you there! 🌍🔬 #DrugDiscovery #ELRIG #DD23

Envisagenics has raised Series B financing to further develop novel therapeutics with our AI-driven drug discovery platform, SpliceCore®. Our platform integrates machine learning and high-performance computing to predict novel and disease-specific alternative splicing isoforms, utilizing one of the world’s largest databases of RNA splicing events. Envisagenics is now a revenue-generating and profitable company with a record 2023. A big thank you to our new and existing investors, including Bristol Myers Squibb, Third Kind Venture Capital, New York City Economic Development Corporation, and Red Cell Partners for partnering with us to unlock the therapeutic potential of RNA. Read the full press release to learn more. https://lnkd.in/eenaHwiE #Envisagenics #SeriesB #Biotech #DrugDiscovery #RNAsplicing #Innovation